NCT01284036

A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects

Ascending Single Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of PF-05230905 Administered Subcutaneously Or Intravenously To Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Ablynx, a Sanofi company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to find the safety and side effects of investigational drug in healthy volunteers. See how quickly investigational drug enters the bloodstream, is distributed in the body, broken down and removed in healthy male and female volunteers. See if your body makes antibodies to this investigational drug (how your immune system responds).

Detailed description

First in human study to collect safety and pharmacokinetics (PK) of single ascending dose in Healthy subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PF-05230905	Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2011-01-26
• Last updated: 2013-01-31

Locations

1 site across 1 country: United States